What happened in the premarket for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock?

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), shares nosedived in the premarket ‎session today as it recorded down -33.49% to reach $61.47. There is no clear answer to why ‎this stock dropped todayother than “confused investors.” ‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

‎The only significant piece of recent news directly affecting this stockwas that ARCT had ‎received approval from the Singapore Health Sciences Authority to initiate a Phase 2 clinical ‎study of its vaccine candidate ARCT-021. In addition to favorable Phase 1/2 results, this ‎study will build on preclinical data,supporting its efficacy.‎

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Read More

Steve Hughes, M.D., Chief Development Officer of Arcturus, said in a ‎statement that upon the basis of our promising Phase 1/2 results, we have decided to ‎advance ARCT-021 into a Phase 2 study. Based on those data and more, we believe our ‎technology can provide a highly effective yet differentiated clinical profile, including a ‎single-dose regimen.‎

Our Phase 2 study will enable us to select the optimal ARCT-021 vaccination ‎regimen for Phase 3 registration studies. We hope to have interim Phase 2 data in ‎early 2021 to provide the basis for our Phase 3 study, which is expected to be ‎initiated in Q2 2021, he added.‎

Most Popular

Related posts